The VE of all COVID-19 vaccines appears to decrease within a few months after vaccination. In a large retrospective analysis of data from the UK, the initial VE for BNT162b2 of around 90% after the second dose dropped drastically to <60% after 25 weeks31. In the same study, the VE ...
In the current study, we used survey data from a nationally representative sample of community-dwelling U.S. adults, conducted from March 2020 to March 2021 to (1) estimate the baseline-symptom-adjusted prevalence of long COVID, (2) show the most commonly reported long COVID symptoms, and ...
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with a range of persistent symptoms impacting everyday functioning, known as post-COVID-19 condition or long COVID. We undertook a retrospective matched cohort study using a UK-based primary care database, Clinica...
If you’re unwell or have symptoms of COVID-19, wait until you feel better before getting vaccinated. If you’ve recently recovered from COVID-19, you don’t need to delay your vaccination. If you’re eligible for the free NHS COVID-19 vaccination, there are several ways you can get...
Remdesivir* shows clinical benefit in non-human primates infected with SARS-CoV2, as published in Nature. June 9, 2020 Health Canada authorizes the use of Remdesivir* in patients with severe COVID-19 symptoms. July 28, 2020 The United Kingdom National Health Service foll...
(NPR) is claiming to be mystified by a siginficant increase in hospital emergency admissions across the United States but does not find the fact that these medical emergencies are all among people already vaccinated against COVID-19 and also all due to people experiencing symptoms consistent with...
97 MOVe-OUT is a double-blind, placebo-controlled phase 3 trial that evaluated molnupiravir therapy starting within 5 days after onset of symptoms in nonhospitalized, unvaccinated patients with confirmed SARS-CoV-2 (including 2.2% patients with active cancer) and demonstrated a relative risk ...
Pragmatic trial evidence from high-income countries among a largely vaccinated population remains an important evidence gap, as does an understanding of whether ivermectin can reduce persistent symptoms or improve function in the longer term. We aimed to determine whether ivermectin speeds recovery and ...
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both pr
The development of several SARS-CoV-2 vaccines has substantially helped reduce morbidity and mortality worldwide. However, breakthrough infections among fully vaccinated people by variants of concern (VOCs) have risen globally1,2,3,4,5,6. Despite the increase in breakthrough cases, vaccine-mediated...